Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis

por Haddox, C L, Mangaonkar, A A, Chen, D, Shi, M, He, R, Oliveira, J L, Litzow, M R, Al-Kali, A, Hogan, W J, Elliott, M A
Publicado 2017

CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before...

por Holtan, S G, Hogan, W J, Elliott, M A, Ansell, S M, Inwards, D J, Porrata, L F, Johnston, P B, Micallef, I N, Lacy, M Q, Gastineau, D A, Litzow, M R
Publicado 2010

European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response

por Begna, K. H., Kittur, J., Gangat, N., Alkhateeb, H., Patnaik, M. S., Al-Kali, A., Elliott, M. A., Hogan, W. J., Litzow, M. R., Pardanani, A., Hanson, C. A., Ketterling, R. P., Tefferi, A.
Publicado 2022

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”

por Begna, K. H., Xu, X., Gangat, N., Alkhateeb, H., Patnaik, M. M., Al-Kali, A., Elliott, M. A., Hogan, W. J., Litzow, M. R., Hook, C. C., Wolanskyj-Spinner, A. P., Mangaonkar, A., He, R., Pardanani, A., Shah, M., Ketterling, R. P., Tefferi, A.
Publicado 2022